AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04539522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-dimensionally corrective exercise for scoliosis
Description: Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
Study NCT04539522 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: Conventional exercise consists a series of spine exercises focusing on core strength training.
Study NCT04264650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an mHealth intervention
Description: The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
Study NCT04111016 — intervention group
Intervention type: BEHAVIORAL
Intervention: Integrated child stimulation, nutrition, lead, arsenic, WASH intervention
Description: The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
Study NCT02092051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with DexCom G4 platina
Study NCT00951522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411 dissolved in sterile saline
Study NCT00951522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo in sterile saline
Study NCT02671539 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1
Description: single subretinal injection
Study NCT02002936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101
Description: SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
Study NCT02209948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02386215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-test
Description: Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing
Study NCT01067599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low nicotine
Description: Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
Study NCT01067599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium nicotine
Description: Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
Study NCT01067599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High nicotine
Description: Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
Study NCT04095663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Colectomy
Description: Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
Study NCT04095663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise.
Study NCT02218086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slackline
Description: Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
Study NCT02218086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wobbling Board
Description: Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
Study NCT02218086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-training
Description: First investigation of the beginners with less than 1 hour experience with slacklining.
Study NCT02218086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fix visual anchor
Description: Professionals have to gaze at a fixed visual anchor during the slacklining.
Study NCT02218086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moving visual anchor
Description: Professionals have to gaze at a moving visual anchor during the slacklining.
Study NCT02218086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-training
Description: Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
Study NCT02218086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slackline vs. standing-on-1-leg vs. control
Description: beginners have to train 9 times \~15minutes within y few weeks.
Study NCT01437098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-2111 CoreValve for TAVI
Description: CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
Study NCT01330589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo for 7 days: PO/TID
Study NCT01187446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total skin electron beam therapy (TSEBT)
Description: TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
Study NCT02118311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
Study NCT01330589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. Johns Wort
Description: For 7 days: 300mg PO/TID
Study NCT01005420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
Study NCT01005420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
Study NCT04437329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, nedaplatin, fluorouracil
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Study NCT04437329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, cisplatin, fluorouracil
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Study NCT04437329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
Study NCT04437329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
Study NCT02118311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
Study NCT04437329 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated-radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
Study NCT00686257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total face mask (interface for NPPV)
Description: NPPV is applied by this mask, as long as NPPV is received.
Study NCT00686257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfort full or RT040 oronasal mask (interface for NPPV)
Description: NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
Study NCT04437329 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity modulated-radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
Study NCT01066546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon tablet for oral administration
Description: 10 mg TID for Week 1, followed by 20 mg TID for remainder of study
Study NCT01966406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Study NCT01966406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No nasogastric tube
Study NCT01030237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 114657
Description: 1 drop both eyes four times a day for 6 weeks
Study NCT02413086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early-stage amputation
Description: Individuals with DFU were given early-stage amputation.
Study NCT02413086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amputation
Description: Individuals with DFU were given amputation.
Study NCT02413086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External herbs chitosan
Description: Wound was given external herbs chitosan after amputation.
Study NCT01030237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soothe XP Lubricant Eye Drops
Description: 1 drop both eyes four times a day for 6 weeks
Study NCT01380145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 Protein + AS15 Adjuvant
Description: recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
Study NCT04707807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IIEF-5
Description: IIEF-15 form will be filled out by all participants
Study NCT05097638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: Patient do spirometry
Study NCT01579799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-lysine
Description: Dose finding study for L-lysine
Study NCT02634307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 8700
Description: Administered as specified in the treatment arm.
Study NCT02656147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR γδT
Description: Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
Study NCT00586755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive Induction-BMT
Description: Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
Study NCT01214200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP)
Description: This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
Study NCT00667017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFT5-dgA immunotoxin
Study NCT00667017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescence activated cell sorting
Study NCT00667017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT01187446 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total skin electron beam therapy (TSEBT)
Description: TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
Study NCT01187446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
Study NCT01080066 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
Study NCT01194843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
Study NCT01194843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological serum
Description: 40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
Study NCT02413086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional gauze
Description: Wound was given traditional gauze after amputation.
Study NCT06277349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Toric multifocal IOL
Description: Implant of Multifocal toric intraocular lens only
Study NCT02910492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Dual-pulse duration laser for the treatment of skin rejuvenation
Study NCT01497665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN1005
Description: 650 mg/m2 IV every 3 weeks
Study NCT00514592 — intervention group
Intervention type: OTHER
Intervention: New Guidelines
Description: New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
Study NCT04004026 — intervention group
Intervention type: OTHER
Intervention: Assesment
Description: 3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
Study NCT02607735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
Study NCT02607735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet administered orally once daily with food
Study NCT04585113 — intervention group
Intervention type: RADIATION
Intervention: CT-scanning
Description: All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
Study NCT00066443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2
Study NCT00066443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
Study NCT00066443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
Study NCT02485405 — intervention group
Intervention type: OTHER
Intervention: Trier social stress test
Description: Volunteers perform Trier social stress test
Study NCT06277349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-toric multifocal IOL
Description: Implant of non-toric multifocal lens plus incisional surgery
Study NCT02280824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CA-TAVR
Description: Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
Study NCT02280824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer Duct Occluder
Study NCT03087942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: 450 mg
Study NCT03087942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW39A
Description: 450 mg
Study NCT03087942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW39A2107
Description: 450 mg
Study NCT00457977 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax (PPSV23)
Description: Injection
Study NCT00457977 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar (PCV7)
Description: Injection
Study NCT03354884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: cabozantinib 60 mg orally once daily
Study NCT01485900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899A
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT00394602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview regarding perceptions of side effects that are related to chemoradiation treatment.
Study NCT00394602 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: 3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
Study NCT01382121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Modeling
Description: Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
Study NCT01382121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: watching a video unrelated to the fitness test and self-efficacy
Study NCT03551600 — intervention group
Intervention type: PROCEDURE
Intervention: Near-infrared spectroscopy (NIRS)
Description: NIRS analyzes regional oxygen saturations (rSO2)